K Peony Yu Sells 9,145 Shares of FibroGen Inc (FGEN) Stock

FibroGen Inc (NASDAQ:FGEN) insider K Peony Yu sold 9,145 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $56.30, for a total value of $514,863.50. Following the completion of the transaction, the insider now owns 182,440 shares in the company, valued at approximately $10,271,372. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of FGEN stock traded up $0.67 during trading hours on Friday, reaching $56.50. The company had a trading volume of 914,507 shares, compared to its average volume of 667,800. FibroGen Inc has a 12 month low of $37.27 and a 12 month high of $68.55. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $4.78 billion, a PE ratio of -54.85 and a beta of 1.74.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.40. FibroGen had a negative return on equity of 16.84% and a negative net margin of 40.58%. The company had revenue of $108.05 million for the quarter, compared to analyst estimates of $72.15 million. During the same quarter last year, the company earned ($0.27) earnings per share. The company’s revenue for the quarter was up 251.5% on a year-over-year basis. On average, equities research analysts anticipate that FibroGen Inc will post -0.93 earnings per share for the current fiscal year.

FGEN has been the topic of several recent research reports. TheStreet lowered FibroGen from a “c-” rating to a “d+” rating in a report on Wednesday, November 21st. Mizuho restated a “buy” rating and issued a $74.00 target price on shares of FibroGen in a report on Monday, December 17th. Citigroup upgraded FibroGen from a “neutral” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Tuesday, December 18th. BidaskClub upgraded FibroGen from a “hold” rating to a “buy” rating in a report on Saturday, December 22nd. Finally, Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a report on Tuesday, January 8th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. FibroGen currently has an average rating of “Buy” and an average target price of $72.40.

A number of institutional investors have recently modified their holdings of FGEN. Meeder Asset Management Inc. lifted its holdings in FibroGen by 622.4% during the fourth quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 529 shares during the period. Intercontinental Wealth Advisors LLC bought a new stake in FibroGen during the fourth quarter worth $37,000. Flinton Capital Management LLC bought a new stake in FibroGen during the fourth quarter worth $44,000. Neuburgh Advisers LLC bought a new stake in FibroGen during the fourth quarter worth $53,000. Finally, Bank of Montreal Can lifted its holdings in FibroGen by 177.3% during the fourth quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 1,101 shares during the period. Institutional investors and hedge funds own 66.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “K Peony Yu Sells 9,145 Shares of FibroGen Inc (FGEN) Stock” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2019/03/15/k-peony-yu-sells-9145-shares-of-fibrogen-inc-fgen-stock-2.html.

FibroGen Company Profile

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

See Also: Different Options Trading Strategies

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit